1. At The Cutting Edge of Developments in the Management of Hyperkalemia

2. Program Goals

3. Recent Clinical Trial Data on Potassium Binders: Patiromer

4. OPAL-HK Phase 3 Pivotal Study Design

5. OPAL-HK Initial Treatment Phase

7. OPAL-HK: Phase 3 Study Part B Effect on Concomitant RAAS Inhibitor Therapy

9. Chronic Diuretic Therapy Does Not Impair the Effectiveness of Patiromer in Hyperkalemic Patients With CKD*

10. Use of Antihypertensive Medications and Hyperkalemia

11. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Healthcare System: Study Design

12. PATHWAY-2 Optimal Treatment for Resistant Hypertension

13. Need for Potassium Binding Agents

14. Recent Clinical Trial Data on Potassium Binders: ZS-9

15. ZS-9*: Potassium Levels During the Acute and Maintenance Phase

16. Long-term Safety and Efficacy of ZS-9 in the Treatment of Hyperkalemia

17. Interim Safety Results of 52-week Trial of ZS-9 in Patients With Hyperkalemia

18. Implications of New and Emerging Potassium Binders in Clinical Practice

19. Hyperkalemia in Patients on Dialysis

20. Frequency of Hyperkalemia Events in Dialysis Patients

21. Serum Potassium and Mortality in Hemodialysis Patients

22. Developments in the Management of Hyperkalemia

23. Abbreviations

24. Abbreviations (cont)